Core Viewpoint - The stock price of Saily Medical closed at 29.50 yuan on August 5, showing a decline of 0.51% compared to the previous trading day, with notable price fluctuations throughout the day [1] Company Overview - Saily Medical's main business includes centralized marketing and service for medical testing, as well as the agency, research, production, and sales of in vitro diagnostic products [1] - The company holds a significant market influence in the medical commercial sector within Hubei province [1] Market Activity - On August 5, the net outflow of main funds was 4.6852 million yuan, with a cumulative net outflow of 276 million yuan over the past five trading days [1] - The trading volume for the day reached 1.055 billion yuan, with a turnover rate of 18.99%, indicating a high level of market activity [1]

Fundraising Overview - The company, Sealy Medical Technology Group Co., Ltd., raised a total of approximately RMB 625.96 million through a private placement of 26,853,709 shares at a price of RMB 23.31 per share, as approved by the China Securities Regulatory Commission in 2018 [1][2] - The net amount raised after deducting issuance costs was confirmed by a verification report from a certified public accounting firm [1] Fund Management and Regulatory Compliance - The company has established a dedicated bank account for the management of the raised funds and signed a tripartite supervision agreement with the bank and the sponsor, ensuring compliance with relevant regulations [2][3] - A new special account was set up at Jiangsu Sushang Bank to manage the funds for the 2018 non-public offering project aimed at expanding the scale of medical testing services, with no changes to the intended use of the funds [2][3] Tripartite Supervision Agreement - The tripartite agreement involves Sealy Medical as Party A, Jiangsu Sushang Bank as Party B, and the sponsor, Xinda Securities, as Party C, ensuring that the funds are used solely for the specified project [3][4] - The agreement stipulates that the funds must not be used for any other purposes and outlines the responsibilities of each party in monitoring and managing the funds [4][5] Fund Usage and Reporting - The company is required to notify the sponsor within five working days of any fund disbursement and provide a detailed expenditure list [5] - The agreement remains effective until all funds are fully utilized and the account is legally closed [5]

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].

Fundraising Overview - The company raised a total of RMB 625,959,956.79 from a non-public offering of A-shares in June 2018, with a net amount of RMB 607,608,016.80 after deducting issuance costs [1] - In 2020, the company issued convertible bonds, raising RMB 543,310,000.00, with a net amount of RMB 533,298,679.25 after related expenses [2] Fund Management - The company has established a special account storage system for the raised funds, with multiple accounts at various banks, including Bank of China and China Merchants Bank [2][4] - The company plans to change the special fundraising account to improve management efficiency and has signed a tripartite supervision agreement with the new bank [5] Board and Supervisory Approval - The board of directors unanimously approved the change of the special fundraising account, and the supervisory board also agreed, stating that the change would not affect the use of funds or harm shareholder interests [6][7] Regulatory Compliance - The company’s actions comply with relevant regulations, including the Shanghai Stock Exchange's rules on fundraising management and usage [6][7]